Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 4;9(11):1501.
doi: 10.3390/healthcare9111501.

Neurological Manifestations and Outcomes in a Retrospective Cohort of Mexican Inpatients with SARS-CoV-2 Pneumonia: Design of a Risk Profile

Silvia García  1   2   3 , Francisco Manuel Cuatepotzo-Burgos  1 , Christian Gabriel Toledo-Lozano  1 , Adriana Balderrama-Soto  2 , Sofía Lizeth Alcaraz-Estrada  4 , Luis Montiel-López  2 , Alberto Hilarión De la Vega-Bravo  2   5 , Paul Mondragón-Terán  2 , Maribel Santosbeña-Lagunes  2   5 , Maricela Escarela-Serrano  2 , Celia Mireya Rodríguez-Martínez  2 , María Del Carmen Méndez-Vidrio  2 , Sandra Muñoz-López  2 , José Alfredo Merino-Rajme  2 , Rodrigo Alberto Rodríguez-Briseño  2 , Fidel Cerda-Téllez  2 , Ramón Mauricio Coral-Vázquez  6   7 , Sergio Sauri-Suárez  2 , Sandra Quiñonez-Aguilar  2 , Juan Antonio Pineda-Juárez  2 , Juan Antonio Suárez-Cuenca  1   2
Affiliations

Neurological Manifestations and Outcomes in a Retrospective Cohort of Mexican Inpatients with SARS-CoV-2 Pneumonia: Design of a Risk Profile

Silvia García et al. Healthcare (Basel). .

Abstract

We analyzed the neurological manifestations in Mexican patients hospitalized with pneumonia due to COVID-19 and investigated the association between demographic, clinical, and biochemical variables and outcomes, including death. A retrospective, analytical study was conducted using the electronic records of patients hospitalized between 1 April 2020 and 30 September 2020. Records of 1040 patients were analyzed: 31.25% died and 79.42% had neurological symptoms, including headache (80.62%), anosmia (32.20%), ageusia (31.96%), myopathy (28.08%), disorientation (14.89%), encephalopathy (12.22%), neuropathy (5.4%), stroke (1.3%), seizures (1.3%), cerebral hemorrhage (1.08%), encephalitis (0.84%), central venous thrombosis (0.36%), and subarachnoid hemorrhage (0.24%). Patients also had comorbidities, such as hypertension (42.30%), diabetes mellitus (38.74%), obesity (61.34%), chronic obstructive pulmonary disease (3.17%), and asthma (2.01%). Factors associated with neurological symptoms were dyspnea, chronic obstructive pulmonary disease, advanced respiratory support, prolonged hospitalization, and worsening fibrinogen levels. Factors associated with death were older age, advanced respiratory support, amine management, chronic obstructive pulmonary disease, intensive care unit management, dyspnea, disorientation, encephalopathy, hypertension, neuropathy, diabetes, male sex, three or more neurological symptoms, and obesity grade 3. In this study we designed a profile to help predict patients at higher risk of developing neurological complications and death following COVID-19 infection.

Keywords: COVID-19; case fatality ratio; neurological symptoms; respiratory infection; risk profile.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Factors associated with the presence of neurological symptoms. OR: odds ratio; CI: confidence interval.
Figure 2
Figure 2
Factors associated with death. ICU: intensive care unit; OR: odds ratio; CI: confidence interval.
See this image and copyright information in PMC

References

    1. Harapan B.N., Yoo H.J. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) J. Neurol. 2021;268:3059–3071. doi: 10.1007/s00415-021-10406-y. - DOI - PMC - PubMed
    1. Mapa en tiemp real de casos de coronavirus por Johns Hopkins School—CVOED—centro virtual de operaciones en emergencias y desastres. [(accessed on 27 August 2021)]. Available online: http://cvoed.imss.gob.mx/mapa_coronavirus/
    1. Tsatsakis A., Calina D., Falzone L., Petrakis D., Mitrut R., Siokas V., Pennisi M., Lanza G., Libra M., Doukas S.G., et al. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem. Toxicol. 2020;146:111769. doi: 10.1016/j.fct.2020.111769. - DOI - PMC - PubMed
    1. Meppiel E., Peiffer-Smadja N., Maury A., Bekri I., Delorme C., Desestret V., Gorza L., Hautecloque-Raysz G., Landre S., Lannuzel A., et al. Neurologic manifestations associated with COVID-19: A multicentre registry. Clin Microbiol Infect. 2021;27:458–466. doi: 10.1016/j.cmi.2020.11.005. - DOI - PMC - PubMed
    1. Carod-Artal F.J. Neurological complications of coronavirus and COVID-19. Rev. Neurol. 2020;70:311–322. doi: 10.33588/RN.7009.2020179. - DOI - PubMed

LinkOut - more resources